

The complicated dialogue between *Helicobacter pylori* and p53

We recently read the interesting paper published in *GUT* elucidating the role of upstream stimulatory factor 1 (USF1) in *Helicobacter pylori* (*Hp*)-induced p53 degradation.¹ The work greatly broadens our knowledge of the interplay between *Hp* and p53 during gastric carcinogenesis. Here we propose some additional exploration, if incorporated in study design, can further deepen our understanding.

The significance of USF1 in gastric carcinogenesis should be acknowledged as the study showed that loss of USF1, on its own, exacerbated the severity of

Hp-induced gastric lesions. However, the underlying mechanism probably warrants further investigation. The authors illustrated that USF1 defect accelerated gastric carcinogenesis through destabilising p53 and subsequently, leading to its degradation. Although mainly regulated at post-translational level, p53 can also be modulated through its transcriptional activity which was shown to be context-dependent.^{2,3} Specifically, as a transcription factor, USF1 has been shown to be capable of binding to the p53 promoter.^{4,5} In this article, the authors showed that the mRNA levels of *USF1* and *TP53* genes were significantly diminished by *Hp* (Figure 3¹), therefore leading to the possibility of decreased transcriptional regulation of *TP53* by USF1. Thus, further research is encouraged to clarify, besides affecting p53 degradation, whether USF1 plays a transcriptional regulatory role in this context.

Additionally, it is premature, based on results in the current study (Figure 7), to draw a conclusion that *Hp*-induced accumulation of USF1 outside the nucleus is a 'point of no return'. Previous studies have shown that DNA double-strand breaks and impairment in mismatch repair induced by *Hp*, if transient, were repairable and reversible after the bacteria were removed and the cells were allowed to grow for another 48 hours.^{6,7} Importantly, some clinical evidence also implied that *Hp* related lesions, including genomic instability, would be reversed 1 year after eradication therapy.⁸ Taken together, it is possible that nuclear depletion of USF1 may partly, if not entirely, reversible as well and the observed irreversibility in the current study may be attributed to a lack of 'recovery period', as camptothecin (CPT) treatment was initiated immediately after several rinses. To permit an additional 48 hours for cellular growth before CPT is added and, meanwhile, keep a record of the dynamics of USF1 alterations is a potential way to provide a more holistic perspective.⁹

Zhi-Hang Tao,¹ Jing-Yuan Fang ¹

State Key Laboratory for Oncogenes and Related Genes, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

Correspondence to Dr Jing-Yuan Fang, State Key Laboratory for Oncogenes and Related Genes, Key Laboratory of Gastroenterology and Hepatology, Ministry of Health, Division of Gastroenterology and Hepatology, Shanghai Institute of Digestive Disease,

Renji Hospital, School of Medicine, Shanghai Jiao Tong University, 145 Middle Shandong Road, Shanghai 200001, China; jingyuanfang@sjtu.edu.cn

Contributors Written by Z-HT. Revised by J-YF.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; internally peer reviewed.

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.



To cite Tao Z-H, Fang J-Y. *Gut* 2020;**69**:2052–2053.

Received 7 January 2020

Accepted 13 January 2020

Published Online First 23 January 2020

Gut 2020;**69**:2052–2053. doi:10.1136/

gutjnl-2020-320630

ORCID iD

Jing-Yuan Fang <http://orcid.org/0000-0003-2282-0248>

REFERENCES

- Costa L, Corre S, Michel V, *et al.* USF1 defect drives p53 degradation during *Helicobacter pylori* infection and accelerates gastric carcinogenesis. *Gut* 2020;**69**:1582–91.
- Meek DW. Tumour suppression by p53: a role for the DNA damage response? *Nat Rev Cancer* 2009;**9**:714–23.
- Saldaña-Meyer R, Recillas-Targa F. Transcriptional and epigenetic regulation of the p53 tumor suppressor gene. *Epigenetics* 2011;**6**:1068–77.
- Hale TK, Braithwaite AW. Identification of an upstream region of the mouse p53 promoter critical for transcriptional expression. *Nucleic Acids Res* 1995;**23**:663–9.
- Reisman D, Rotter V. The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene. *Nucleic Acids Res* 1993;**21**:345–50.
- Kim JJ, Tao H, Carloni E, *et al.* Helicobacter pylori impairs DNA mismatch repair in gastric epithelial cells. *Gastroenterology* 2002;**123**:542–53.
- Toller IM, Neelsen KJ, Steger M, *et al.* Carcinogenic bacterial pathogen Helicobacter pylori triggers DNA double-strand breaks and a DNA damage response in its host cells. *Proc Natl Acad Sci U S A* 2011;**108**:14944–9.
- Nardone G, Staibano S, Rocco A, *et al.* Effect of Helicobacter pylori infection and its eradication on cell proliferation, DNA status, and oncogene expression in patients with chronic gastritis. *Gut* 1999;**44**:789–99.
- Wei J, Nagy TA, Vilgelm A, *et al.* Regulation of p53 tumor suppressor by Helicobacter pylori in gastric epithelial cells. *Gastroenterology* 2010;**139**:1333–43.